Connection

CHARLES FOULDS to Cell Line, Tumor

This is a "connection" page, showing publications CHARLES FOULDS has written about Cell Line, Tumor.
Connection Strength

0.267
  1. Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
    View in: PubMed
    Score: 0.090
  2. Research resource: expression profiling reveals unexpected targets and functions of the human steroid receptor RNA activator (SRA) gene. Mol Endocrinol. 2010 May; 24(5):1090-105.
    View in: PubMed
    Score: 0.051
  3. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.035
  4. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.027
  5. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
    View in: PubMed
    Score: 0.026
  6. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
    View in: PubMed
    Score: 0.022
  7. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012 May; 122(5):1869-80.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.